UBS cuts BioXcel to neutral; cites regulatory issues, financing
https://seekingalpha.com/news/4069650-ubs-cuts-bioxcel-to-neutral-cites-regulatory-issues-financing?source=feed_sector_healthcare
Feb 21, 2024 - UBS has downgraded BioXcel Therapeutics (BTAI) to neutral, citing too much uncertainty about the company’s financing, regulatory alignment with the FDA, and end
0
UBS Group AG (UBS) Aided by Strategic Buyouts Amid High Costs
https://www.zacks.com/stock/news/2232509/ubs-group-ag-ubs-aided-by-strategic-buyouts-amid-high-costs?cid=CS-ZC-FT-analyst_blog|company_news_-_finance_sector-2232509
Feb 27, 2024 - Business restructuring plans and strategic acquisitions support UBS Group AG's (UBS) financials. However, rising costs will likely limit bottom-line growth.
0
UBS (UBS) Up 5% Since Last Earnings Report: Can It Continue?
https://www.zacks.com/stock/news/2237436/ubs-ubs-up-5-since-last-earnings-report-can-it-continue?cid=CS-ZC-FT-realtime_blog-2237436
Mar 07, 2024 - UBS (UBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
0
UBS sees Lilly GLP-1/sleep apnea study falling short of Street estimates
https://seekingalpha.com/news/4079564-ubs-sees-lilly-glp-1sleep-apnea-study-falling-short-of-street-estimates?source=feed_sector_healthcare
Mar 14, 2024 - UBS said it believes that upcoming data for Eli Lilly’s (LLY) GLP-1 drug tirzepatide in the treatment of sleep apnea will come in below Street expectations. Read more here.
0
UBS chief's surprise return to the Swiss banking giant bagged him a $15.9 million paycheck
https://www.cnbc.com/2024/03/28/ubs-chiefs-surprise-return-to-the-swiss-banking-giant-bagged-him-a-15point9-million-paycheck.html
Mar 28, 2024 - UBS CEO Sergio Ermotti earned 14.4 million Swiss francs ($15.9 million) in 2023 after his surprise return to the helm of the Swiss banking giant.
0
Swiss banking giant UBS to launch share buyback of up to $2 billion
https://www.cnbc.com/2024/04/02/swiss-banking-giant-ubs-to-launch-share-buyback-of-up-to-2-billion.html
Apr 01, 2024 - UBS on Tuesday announced a new share repurchase program of up to $2 billion, with up to $1 billion of that total expected to take place this year.
0
BSBR vs. UBS: Which Stock Is the Better Value Option?
https://www.zacks.com/stock/news/2249240/bsbr-vs-ubs-which-stock-is-the-better-value-option?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2249240
Apr 02, 2024 - BSBR vs. UBS: Which Stock Is the Better Value Option?
0
UBS Group's (UBS) JV to Buy CS' Japanese Wealth Management Unit
https://www.zacks.com/stock/news/2252187/ubs-group-s-ubs-jv-to-buy-cs-japanese-wealth-management-unit?cid=CS-ZC-FT-analyst_blog|company_news_-_finance_sector-2252187
Apr 08, 2024 - UBS Group's (UBS) JV is set to acquire Credit Suisse's wealth management unit in Japan. Per the deal, Credit Suisse's advisors and wealth management assets are set to be transferred to the JV.
0
UBS Group (UBS) to Swap Stake in CS Securities in China
https://www.zacks.com/stock/news/2252802/ubs-group-ubs-to-swap-stake-in-cs-securities-in-china?cid=CS-ZC-FT-analyst_blog|company_news_-_finance_sector-2252802
Apr 09, 2024 - UBS Group (UBS) is seeking to swap its holding in Credit Suisse Securities in order to gain the complete ownership of its joint venture UBS Securities in China.
0
UBS sees earnings heading for strongest pace of quarterly growth in more than 2 years
https://seekingalpha.com/news/4093721-ubs-sees-q1-earnings-heading-for-strongest-pace-of-growth-in-more-than-2-years?source=feed_sector_healthcare
Apr 24, 2024 - UBS sees corporate earnings heading toward biggest quarterly growth rate since 2021. Read more here.
0
Page 1>